Apollomics Inc. Class A Ordinary Shares (NASDAQ:APLM) — Market Cap & Net Worth
Market Cap & Net Worth: Apollomics Inc. Class A Ordinary Shares (APLM)
Apollomics Inc. Class A Ordinary Shares (NASDAQ:APLM) has a market capitalization of $30.09 Million ($30.09 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23822 globally and #5089 in its home market, demonstrating a -2.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apollomics Inc. Class A Ordinary Shares's stock price $13.96 by its total outstanding shares 2196052 (2.20 Million). Review how much debt does Apollomics Inc. Class A Ordinary Shares carry to assess the company's total debt and financial obligations.
Apollomics Inc. Class A Ordinary Shares Market Cap History: 2021 to 2026
Apollomics Inc. Class A Ordinary Shares's market capitalization history from 2021 to 2026. Data shows change from $2.18 Billion to $30.66 Million (-60.73% CAGR).
Index Memberships
Apollomics Inc. Class A Ordinary Shares is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #685 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2258 of 3165 |
Weight: Apollomics Inc. Class A Ordinary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Apollomics Inc. Class A Ordinary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apollomics Inc. Class A Ordinary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.83x
Apollomics Inc. Class A Ordinary Shares's market cap is 4.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.18 Billion | $2.00K | -$94.80 Million | 1090339.82x | N/A |
| 2022 | $2.28 Billion | $323.00K | -$240.81 Million | 7043.68x | N/A |
| 2023 | $211.92 Million | $821.00K | -$172.60 Million | 258.12x | N/A |
| 2024 | $21.41 Million | $198.00K | -$53.86 Million | 108.14x | N/A |
| 2025 | $41.06 Million | $8.50 Million | -$10.94 Million | 4.83x | N/A |
Competitor Companies of APLM by Market Capitalization
Companies near Apollomics Inc. Class A Ordinary Shares in the global market cap rankings as of June 18, 2026.
Key companies related to Apollomics Inc. Class A Ordinary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Apollomics Inc. Class A Ordinary Shares Historical Marketcap From 2021 to 2026
Between 2021 and today, Apollomics Inc. Class A Ordinary Shares's market cap moved from $2.18 Billion to $ 30.66 Million, with a yearly change of -60.73%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.66 Million | -25.33% |
| 2025 | $41.06 Million | +91.74% |
| 2024 | $21.41 Million | -89.90% |
| 2023 | $211.92 Million | -90.69% |
| 2022 | $2.28 Billion | +4.33% |
| 2021 | $2.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Apollomics Inc. Class A Ordinary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.09 Million USD |
| MoneyControl | $30.09 Million USD |
| MarketWatch | $30.09 Million USD |
| marketcap.company | $30.09 Million USD |
| Reuters | $30.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more